In Brief This Week: Bruker; Hologic, Immucor; Cancer Genetics; New England Biolabs; Genewiz; Genedata | GenomeWeb

NEW YORK (GenomeWeb News) – Investment bank Jefferies this week upgraded Bruker's stock to Buy from Hold and upped its price target on the stock from $20 to $25. "We have increased confidence in [Bruker's] intermediate-term profit and cash flow trajectories, and see more than [an] adequate degree of conservatism in its formal 2013 outlook," Jefferies analyst Jon Wood wrote in a note published Thursday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.